Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>G Sachs Lifts WUXI BIO's TP to $23.4 w/ Lower Earnings Forecasts
Recommend 9 Positive 18 Negative 4 |
||||
|
||||
|
WUXI BIO (02269.HK)'s 2H24 revenue surged by 18.3% YoY to RMB10.1 billion, reaching the upper end of guidance, according to a report from Goldman Sachs. Looking ahead to 2025, management expected the company's revenue to grow by 12-15% YoY, ongoing operations to climb by 17-20% YoY, and profit margins to continue picking up. With increased contributions from later-stage projects, management also predicted revenue growth to further accelerate in 2026 and beyond. Goldman Sachs cut its 2025-26 EPS forecasts for WUXI BIO by 0.5% and 0.9% respectively but raised its target price from $20.8 to $23.4, with a Neutral rating. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
